The pathogenetic relevance of methicillin-resistant Staphylococcus aureus in chronic wounds;Die pathogenetische bedeutung von methicillin resistentem Staphylococcus aureus (MRSA) in chronischen wunden

Vasa - Journal of Vascular Diseases

Volumn 32, Issue 3, 2003, Pages 131-138

  Dissemond, Joachim ^a   Goos, M ^a   Esser, S ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

MRSA; ORSA; Staphylococcus aureus; Vancomycin

Indexed keywords

ANTIBIOTIC AGENT; DALFOPRISTIN PLUS QUINUPRISTIN; LINEZOLID; OCTENIDINE; PSEUDOMONIC ACID; TEICOPLANIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL COLONIZATION; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; REVIEW; WOUND; WOUND HEALING; WOUND INFECTION;

EID: 0141540507     PISSN: 03011526     EISSN: None     Source Type: Journal    
DOI: 10.1024/0301-1526.32.3.131     Document Type: Review

References (78)

1. Amagai M, Matsuyoshi N, Wang ZH, Andl C, Stanley JR. Toxin in bullous impetigo and staphylococcal scalded-skin syndrome targets desmoglein 1. Nature Med 2000; 6: 1275-7.
2. Ameen H, Moore K, Lawrence JC, Harding KG. Investigating the bacterial barrier properties of four contemporary wound dressings. J Wound Care 2000; 9: 385-8.
3. Anonymous. Staphylococcus aureus resistant to vancomycin-United States 2002. MMWR Morb Mortal Wkly Rep 2002; 51: 565-7.
4. Bonn D. Maggot therapy: an alternative for wound infection. Lancet 2000; 356: 1174.
5. Boyce JM. Methicillin-resistant Staphylococcus aureus: a continuing infection control challenge. Eur J Clin Microbiol Infect Dis 1994; 13: 45-9.
6. Chambers HF. Methicillin resistance in staphylococci. Molecular and biochemical basis and clinical implications. Clin Microbiol Rev 1997; 10: 781-91.
7. Colsky AS, Kirsner RS, Kerdel FA. Analysis of antibiotic susceptibilities of wound flora in hospitalised dermatology patients: the crisis of antibiotic resistance has come to the surface. Arch Dermatol 1998; 134:1006-9.
8. Cookson B. Failure of mupiricin-resistant staphylococcus to inactivate mupirocin. Eur J Clin Microbiol Infect Dis 1989; 8: 1038-40.
9. Cosgrove SE, Sakoulas G, Perencevich EN, Schwaber MJ, Karchmer AW, Carmeli Y. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis 2003; 36: 53-9.
10. Dissemond J, Koppermann M, Esser S, Schultewolter T, Goos M, Wagner SN. Therapie eines Methicillin-resistenten Staphylokokkus aureus (MRSA) im Rahmen der Behandlung eines chronischen Ulcus mittels Biochirurgie. Hautarzt 2002; 53: 608-12.
11. Filius PM, Gyssens IC. Impact of increasing antimicrobial resistance on wound management. Am J Clin Dermatol 2002; 3: 1-7.
12. Fleischmann W, Russ, Westhauser A, Stampehl M. Die Vakuumversiegelung als Trägersystem für eine gezielte lokale Medikamentenapplikation bei Wundinfekten. Unfallchirurg 1998; 101: 649-54.
13. Frenay HM, Vandenbrocke-Grauls, CM, Molkenboer MJ, Verhoef J. Long-term carriage, and transmission of methicillin-resistant Staphylococcus aureus after discharge from hospital. J Hosp Infect 1992; 22: 207-15.
14. Ge Y, MacDonald D, Henry MM, Hait HI, Nelson KA, Lipsky BA, Zasloff MA, Holroyd KJ. In vitro susceptibility to pexiganan of bacteria isolated from infected diabetic foot ulcers. Diagn Microbiol Infect 1999; 35: 45-53.
15. Gelder G, Zwing M, Trautmann M, Georgieff M, Wiedeck H. Therapie und Prophylaxe bei MRSA-Infektionen auf Intensivstationen. Intensivmed 1999; 36: 612-8.
16. Gillitzer R. Modernes Wundmangement. Hautarzt 2002; 53: 130-47.
17. Gloor M, Becker A, Wasik B, Kniehl E. Triclosan, a topical dermatologic agent. In vitro- and in vivo studies on the effectiveness of a new preparation in the New German Formulary. Hautarzt 2002; 53: 724-9.
18. Gonzalez-Zorn B, Courvalin P. vanA-mediated high level glycopeptide resistance in MRSA. Lancet Infect Dis 2003; 3: 67-8.
19. Grohs P, Kitzis MD, Gutmann L. In vitro bactercidal activities of linezolid in combination with vancomycin, gentamycin, ciprofloxacin, fusidic acid, and rifampin against staphylococcus aureus. Antimicrob agents chemother 2003; 47: 418-20.
20. Halbert AR, Stacey MC, Rohr JB, Jopp-McKay A. The effect of bacterial colonization on venous ulcer healing. Australas J Dermatol 1992; 33: 75-80.
21. Harbarth S, Dharan S, Liassine N, Herrault P, Auckenthaler R, Pittet D. Randomized, placebo-controlled, double-blind trial to evaluate the efficacy of mupirocin for eradicating carriage of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 1999; 43: 1412-6.
22. Harder J, Bartels J, Christophers E, Schröder JM. Isolation and characterization of human beta defensin-3, a novel human inducible peptide antibiotic. J Biol Chem 2001; 276: 5707-13.
23. Hernandez R. Systemic antibiotics: a review and their use in chronic wounds. Dermatologic Therapy 1999; 9: 44-62.
24. Hernandez-Richter T, Schardey HM, Heiss MM, Lohlein F, Schildberg FW. Experimental study of antiseptic (tauroline, taurilidine) and antibiotic (sulmycin implant) drugs in vascular prothesis infections in a standardized infection model. Zentralbl Chir 2001; 126: 407-12.
25. Heudorf U, Bremer V, Heuck D. Methicillin-resistant Staphylococcus aureus in long-term care facilities for the aged in Frankfurt am Main, Germany, in 1999. Gesundheitswesen 2001; 63: 447-54.
26. Hiramatsu J. The emergence of staphylococcus aureus with reduced susceptibility to vancomycin in Japan. Am J Med 1998; 104: 7-10.
27. Hoeger PH, Lenz W, Boutonnier A, Fournier JM. Staphylococcal skin colonization in children with atopic dermatitis: Prevalence, and transmission of toxic and nontoxic strains. J Infect Dis 1992; 165: 1064-8.
28. Huang SS, Platt R. Risk of Methicillin-Resistant Staphylococcus aureus Infection after Previous Infection or Colonization. Clin Infect Dis 2003; 36: 281-5.
29. Ibelings MM, Bruining HA. Methicillin-resistant Staphylococcus aureus: acquisition and risk of death in patients in the intensive care unit. Eur J Surg 1998; 164: 411-8.
30. Ida T, Tsushima M, Ishii T, Atsumi K, Tamura A. CP6679, a new injectable cephalosporin with brad spectrum and potent activities against methicillin-resistant staphylococcus aureus and Pseudomonas aeruginosa. J Infect Chemother 2002; 8: 138-44
31. Jevons MP. Celbenin resistant staphylococci. Br Med J 1961; 1: 124-5.
32. Kac G, Buu-Hoi A, Herisson E, Biancardini P, Debure C Methicillin-resistent staphylococcus aureus. Nosocomial acquisition and carrier state in a wound care center. Arch Dermatol 2000; 136: 735-9.
33. Kloth LC. Physical modalities in wound management: UVC, therapeutic heating and electrical stimulation. Ostomy Wound Manage 1995; 41: 18-27.
34. König DP, Randerath O, Hackenbroch MH. Nosokomiale Infektionen mit Methicillin-resistenten Staphylococcus aureus (MRSA) und epidermidis (MRSE) Stämmen. Unfallchirurg 1999; 102: 323-8.
35. Lackey DB, Groziak MP, Sergeeva M, Beryt M, Boyer C, Stroud RM, Sayre P, Park JW, Johnston P, Salomon D, Shepard HM, Pegram M. Enzyme-catalyzed therapeutic agent (ECTA) design: activation of the antitumor ECTA compound NB1011 by thymidylate synthase. Biochem Pharmacol 2001; 61: 179-89.
36. Lamb HM, Wiseman LR. Pexiganan acetate. Drugs 1998; 56: 1047-52.
37. Leclercq R. Safeguarding future antimicrobial options: strategies to minimize resistance. Clin Microbiol Infect 2001; 7: 18-23
38. Li Q, Lee JY, Castillo R, Hixon MS, Pujol C, Doppalapudi VR, Shepard HM, Lobl TJ, Chan MF. NB2001, a novel antibacterial agent with brad-spectrum activity and enhanced potency against beta-lactamase-producing strains. Antimicrob Agents Chemother 2002; 46: 1262-8.
39. Linde HJ, Lehn N. Methicillin-resistenter Staphylococcus aureus (MRSA). Hautarzt 2002; 53: 690-701.
40. Lindenmayer JM, Schoenfeld S, O'Grady R, Carney JK. Methicillin-resistant Staphylococcus aureus in a high school wrestling team and the surrounding community. Arch Intern Med 1998;158: 895-9.
41. Lowy FD. Staphylococcus aureus infections. N Engl J Med 1998; 339:520-32.
42. Malouin F, Blais J, Chamberland S, Hoang M, Park C, Chan C, Mathias K, Hakem S, Dupree K, Liu E, Nguyen T, Dudley MN. RWJ-54428 (MC-02,479), a New Cephalosporin with High Affinity for Penicillin-Binding Proteins, Including PBP 2a, and Stability to Staphylococcal Beta-Lactamases. Antimicrob Agents Chemother 2003; 47: 658-64.
43. McMurry LM, Oethinger M, Levy SB. Triclosan targets lipid synthesis. Nature 1998; 394: 531-2.
44. Mertz PM, Oliveira-Gandia MF, Davis SC. The evaluation of a cadoxomer iodine wound dressing on methicillin resistant staphylococcus aureus (MRSA) in acute wounds. Dermatol Surg 1999; 25: 89-93.
45. Muder RR, Brennen C, Wagener MM, Vickers RM, Rihs JD, Hancock GA, Yee YC, Miller JM, Yu VL. Methicillin-resistant Staphylococcal colonisation and infection in a long-term care facility. Ann Intern Med 1991; 114: 107-12.
46. Natarajan S, Williamson D, Grey J, Harding KG, cooper RA. Healing of an MRSA-colonized, hydroxyurea-induced leg ulcer with honey. J Dermatolog Treat 2001; 12: 33-6.
47. Navon-Venezia S, Feder R, Gaidukov L, Carmeli L, Mor A. Antibacterial properties of dermaseptin S4 derivates with in vivo activity. Antimicrob Agents Chemother 2002; 46: 689-94.
48. O'Meara S, Cullum N, Majid M, Sheldon T. Systemic review of wound care management: (3) antimicrobial agents for chronic wounds; (4) diabetic foot ulceration. Health Technol Assessment 2000;4:1-237.
49. Ohwada A, Sekiya M, Hanaki H, Arai KK, Nagaoka I, Hori S, Tominaga S, Hiramatsu K, Fukuchi Y. DNA vaccination by mecA sequence evokes an antibacterial immune response against methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 1999; 44: 767-74
50. Okano M, Nagouchi S, Tabata K, Matsumoto Y. Topical gentian violet for cutaneous infection and nasal carriage with MRSA. Int J Dermatol 2000; 39: 942-4.
51. Oliveira DC, de Lencastre H. Multiplex PCR strategy for rapid identification of structural types and variants of the mec element in methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2002; 46: 2155-61.
52. Paladino JA. Linezolid: an oxazolidinone antimicrobial agent. Am J Health Syst Pharm 2002; 59: 2413-25.
53. Paradisi F, Corti G, Messeri D. Antistaphylococcal (MSSA, MRSA, MSSE, MRSE) antibiotics. Med Clin North Am 2001; 85: 1-17.
54. Pittet D, Hugonnet S, Harbarth S, Mourouga P, Sauvan V, Touveneau S, Perneger TV. Effectiveness of a hospital-wide programme to improve compliance with hand hygiene. Infection Control Programme. Lancet 2000; 356: 1307-12.
55. Pujol M, Pena C, Pallares R, Ariza J, Ayats J, Dominguez MA, Gudiol F. Nosocomial Staphylococcus aureus bacteriemia among nasal carriers of methicillin-resistant and methicillin-susceptible strains. Am J Med 1996; 100: 509-16.
56. Reimer K, Wichelhaus TA, Schafer V, Rudolph P, Kramer A, Wutzler P, Ganzer D, Fleischer W. Antimicrobial effectiveness of polyvidone-iodine and consequences for new application areas. Dermatology 2002; 204: 114-20.
57. RKI. Erstes Auftreten von MRSA mit verminderter Glykopeptidresistenz in Deutschland nachgewiesen. Epidem Bull RKI 1998; 36: 255-6.
58. RKI. Zunahme von MRSA in deutschen Krankenhäusern. Epidem Bull RKI 2000; 9: 70-1.
59. Roghmann MC, Siddiqui A, Plasance K, Standiford H. MRSA colonization and the risk of MRSA bacteriemia in hospitalized patients with chronic ulcers. J Hosp Infect 2001; 47: 98-103.
60. Scharffetter-Kochanek K, Schüller J, Meewes C, Hinrichs R, Eich D, Eming S, Wenk J, Wlaschek M. Das chronisch venöse Ulcus cruris. JDDG 2003; 1: 58-67.
61. Scharffetter-Kochanek K, Wlaschek M, Brenneisen P, Schauen M, Blaudschun R, Wenk J. UV-induced reactive oxygen species in photocarcinogenesis and photoaging. Biol Chem 1997; 378: 1247-57.
62. Schröder JM. Antimikrobielle Peptide. Hautarzt 2002; 53: 424-35.
63. Shinefield H, Black S, Fattom A, Horwith G, Rasgon S, Ordonez J, Yeoh H, Law D, Robbins JB, Schneerson R, Muenz L, Fuller S, Johnson J, Fireman B, Alcorn H, Naso R. Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis. N Engl J Med 2002; 346: 491-6.
64. Sieradzki K, Roberts RB, Haber SW, Tomasz A. The development of vancomycin resistance in a patient with methicillin-resistance Staphylococcus aureus infection. N Engl J Med 1999; 340:517-23.
65. Stevens DL, Smith LG, Bruss JB, McConnell-Martin MA, Duvall SE, Todd WM, Hafkin B. Randomized comparison of linezolid versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections. Microb Agents Chemother 2000;44:3408-13.
66. Swanston WH. Methicillin resistant staphylococcus aureus. West Indian Med J 1999; 48: 20-2.
67. Thai TP, Houghton PE, Campell KE, Wodbury MG. Ultraviolet light C in the treatment of chronic wounds with MRSA: a case study. Ostomy Wound Management 2002; 48: 52-60.
68. Towner KJ, Talbot DC, Curran R, Webster CA, Humphreys H. Development and evaluation of a PCR-based immunoassay for the rapid detection of methicillin-resistant Staphylococcus aureus. J Med Microbiol 1998; 47: 607-13.
69. Tsiodras S, Gold HS, Sakoulas G, Eliopoulos GM, Wennersten C, Venkataraman L, Moellering RC, Ferraro MJ. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 2001;358:207-8.
70. von Eiff C, Peters G. Comparative in-vitro activities of moxifloxacin, trovafloxacin, quinupristin/dalfopristin and linezolid against staphylococci. J Antimicrobial Chemotherapy 1999; 43: 569-73.
71. Voss A, Machka K, Lenz W, Milatovic D. Vorkommen, Häufigkeit und Resistenzverhalten von Methicillin-resistenten Staphylococcus aureus Stämmen in Deutschland. Dtsch Med Wschr 1992;117:1907-12.
72. Voss A, Milatovic D, Wallrauch Schwarz C, Rosdahl VT, Braveny I. Methicillin-resistant staphylococcus aureus in Europe. Eur J Clin Microbiol Infect Dis 1994; 13: 50-5.
73. Westh H, Hougaard D, Vuust J, Rosdahl VT. Prevalence of erm gene classes in erythromycin resistant staphylococcus aureus strains isolated between 1959 and 1988. Antimicrob Agents Chemother 1995; 39: 369-73.
74. Whitby M, McLaws ML, Berry G. Risk of death from methicillin-resistant staphylococcus aureus bacteraemia: a meta-analysis. Med J Aust 2001; 175: 264-7.
75. Wright JB, Lam K, Burrell RE. Wound management in an era of increasing bacterial antibiotic resistance: a role for topical silver treatment. Am J Infect Control 1998; 26: 572-7.
76. Zabel LT, Lenz W, Schwab E. Molekulare und phänotypische Charakterisierung von Methicillin-resistenten Staphylococcus aureus-Isolaten. Unfallchirurg 2000; 103: 557-63.
77. Zasloff M. Antimicrobial peptides of multicellular organisms. Nature 2002; 415: 389-95.
78. Zeina B, Greenman J, Purcell WM, Das B. Killing of cutaneous microbial species by photodynamic therapy. Br J Dermatol 2001; 144: 274-8.